To the Editor, Genital psoriasis develops in more than onethird of patients who have psoriasis.1 The treatment of genital psoriasis is challenging because the genital skin is thin and sensitive to some therapies. Topical treatments, including corticosteroids (TCS) and topical calcineurin inhibitors (TCI), are the firstline recommendation of treating genital psoriasis.2 However, TCS and TCI could not improve genital psoriasis for their limitations of efficacy, tolerability, and side effects. Crisaborole, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor, is approved in 2016 as the topical treatment of mildmoderate atopic dermatitis (AD) in children and adults.3 Crisaborole increases levels of intracellular cyclic adenosine monophosphate, which decreases the production of proinflammatory cytokines, including Th1 cytokines (TNFα, interferonγ), Th2 cytokines (IL4, Il13), and IL17.4 Here, we report case series of genital psoriasis successfully treated with topical crisaborole.
[1]
W. Liao,et al.
Genital and Inverse/Intertriginous Psoriasis: An Updated Review of Therapies and Recommendations for Practical Management
,
2021,
Dermatology and Therapy.
[2]
K. Reynolds,et al.
Treatments for inverse psoriasis: a systematic review
,
2020,
The Journal of dermatological treatment.
[3]
J. Werth,et al.
Crisaborole and atopic dermatitis skin biomarkers: an intrapatient randomized trial.
,
2019,
The Journal of allergy and clinical immunology.
[4]
M. Lebwohl,et al.
Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults.
,
2016,
Journal of the American Academy of Dermatology.